Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Island Pharmaceuticals Ltd ( (AU:ILA) ) just unveiled an update.
Island Pharmaceuticals has successfully enrolled all subjects in the Phase 2b therapeutic arm of its ISLA-101 clinical trial for treating dengue fever. This milestone supports their exploration of ISLA-101’s potential as both a prophylactic and therapeutic option. High-level results from this phase are expected by April 2025, with full data anticipated in Q4 FY2025. The successful completion of this trial phase could enhance Island’s positioning within the pharmaceutical industry, potentially leading to FDA approval and eligibility for a Priority Review Voucher, expediting future drug approvals.
More about Island Pharmaceuticals Ltd
Island Pharmaceuticals Ltd is an Australian company specializing in repurposing drugs to address unmet needs for antiviral therapeutics targeting infectious diseases. Their lead product, ISLA-101, is being developed for the prevention and treatment of dengue fever and other mosquito-borne diseases.
YTD Price Performance: 0%
Average Trading Volume: 242,344
Technical Sentiment Consensus Rating: Sell
Current Market Cap: A$30.88M
Find detailed analytics on ILA stock on TipRanks’ Stock Analysis page.
